Avis Budget Group, Inc. (CAR)
$
135.56
-12.89 (-9.51%)
Key metrics
Financial statements
Free cash flow per share
-46.6761
Market cap
4.8 Billion
Price to sales ratio
0.4102
Debt to equity
-9.9613
Current ratio
0.7245
Income quality
-3.7159
Average inventory
0
ROE
0.3205
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Avis Budget Group, Inc., along with its subsidiaries, provides a comprehensive range of car and truck rentals, car sharing, and ancillary services to both businesses and consumers. The company operates under the Avis brand, which delivers premium vehicle rental and mobility solutions tailored for the commercial and leisure segments of the travel industry. Furthermore, the Budget Truck brand specializes in local and one-way truck and cargo van rentals, boasting a fleet of approximately 20,000 vehicles available through a network of around 465 dealer-operated and 385 company-operated locations across the continental United States, serving consumer and light commercial needs. Additionally, the Zipcar brand enhances the offering with its car-sharing network. Avis Budget Group also manages several other car rental brands, including Budget, Payless, Apex, Maggiore, MoriniRent, FranceCars, Amicoblue, Turiscar, and ACL Hire. The company provides a variety of optional insurance products and coverages, such as supplemental liability, personal accident, personal effects protection, emergency sickness protection, and automobile towing protection, alongside cargo insurance options. Additional offerings include fuel service alternatives, roadside assistance, electronic toll collection services, curbside delivery, tablet rentals, satellite radio access, portable navigation units, and child safety seat rentals. The company also supplies moving equipment and accessories, such as hand trucks and furniture pads, as well as a Business Intelligence solution through an online portal for corporate travel. Avis Budget Group, Inc. operates in approximately 10,400 locations globally. The financial data pertains to the fiscal year 2025 during which the company recorded an operating income of $1,281,000,000.00 reflecting its earnings from core operations. The earnings per share (EPS) is reported at -$25.25 indicating the company's profitability on a per-share basis. Furthermore, the net total of other income and expenses is -$2,210,000,000.00 reflecting non-core financial activities, while the company earned an interest income of $0.00 showcasing its financial investments. In the investment landscape, the stock of Avis Budget Group, Inc. is reasonably priced at $157.66 appealing to a broad range of investors. The stock has an average trading volume of 665,418.00 indicating moderate liquidity. With a mid-range market capitalization of $4,779,662,865.00 the company is recognized as a steady performer within its domain. It is a key player in the Rental & Leasing Services industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Industrials sector, driving innovation and growth.
Is Avis Budget Group, Inc. (CAR) a good investment?
Investing in Avis Budget Group, Inc. (CAR) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Avis Budget Group, Inc. (CAR)'s stock forecast?
Analysts predict Avis Budget Group, Inc. stock to fluctuate between $58.88 (low) and $212.81 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Avis Budget Group, Inc.'s market capitalization?
As of 2026-03-30, Avis Budget Group, Inc.'s market cap is $4,779,662,865, based on 35,258,652 outstanding shares.
How does Avis Budget Group, Inc. compare to competitors like Caterpillar Inc.?
Compared to Caterpillar Inc., Avis Budget Group, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Avis Budget Group, Inc. pay dividends?
Avis Budget Group, Inc. pays dividends. The current dividend yield is 5.19%, with a payout of $10 per share.
How can I buy Avis Budget Group, Inc. (CAR) stock?
To buy Avis Budget Group, Inc. (CAR) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CAR. Place an order (Market, Limit, etc.).
What is the best time to invest in Avis Budget Group, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Avis Budget Group, Inc. stock ever split?
Avis Budget Group, Inc.'s last stock split was 1:10 on 2006-09-05.
How did Avis Budget Group, Inc. perform in the last earnings report?
Revenue: $11,652,000,000 | EPS: -$25.25 | Growth: -50.71%.
Where can I find Avis Budget Group, Inc.'s investor relations reports?
Visit https://www.avisbudgetgroup.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Avis Budget Group, Inc.?
You can explore historical data from here
What is the all-time high and low for Avis Budget Group, Inc. stock?
All-time high: $545.11 (2021-11-02) | All-time low: $54.03 (2025-03-13).
What are the key trends affecting Avis Budget Group, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
fool.com
These will be sold from time to time in a public offering. Investor fears of dilution were justified, to a degree.
prnewswire.com
Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-cel trial status SAN JOSE, Calif., March 30, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Department at Moffitt Cancer Center and principal investigator for the Company's ongoing ovarian cancer CAR-T therapy Phase 1 trial, will be presenting at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, being held April 10 – 13, 2026, in San Juan, Puerto Rico.
benzinga.com
Travelers across the U.S. are facing hours‑long security lines as reduced TSA staffing slows airport operations, according to Bloomberg. With air travel becoming increasingly unreliable, investors are betting that more people will choose to drive and rent cars rather than risk missing flights.
zacks.com
Car rental stocks surged on Thursday after Hertz (HTZ) reported a significant increase in website traffic as travelers look for alternatives to flying amid a TSA shortage.
fool.com
Investors also see potential for a short squeeze on the vehicle rental giant. We shouldn't forget in which direction oil prices are traveling, however.
seekingalpha.com
Lyell Immunopharma is a CAR-T developer with a single pivotal asset, ronde-cel, targeting LBCL and showing superior early efficacy and safety data. Ronde-cel's 93% ORR, 76% CR, and ~18-month mPFS in 3L+ LBCL patients outperformed approved peers, supporting a $1B+ peak sales opportunity. Valuation estimates suggest LYEL equity value of ~$45–55 per share, with the current price reflecting moderate success probability; pivotal data in 2027 is key.
zacks.com
Avis Budget (CAR) reported earnings 30 days ago. What's next for the stock?
seekingalpha.com
Caribou Biosciences offers the strongest allogeneic CAR-T data to date, with efficacy and safety rivaling approved autologous products. CRBU trades near net cash value, implying the market assigns minimal value to its pipeline despite RMAT designation and promising Phase 1 results. Key risks include dilution, regulatory hurdles, and competition from in vivo CAR-T, but CRBU's CRISPR chRDNA editing and leadership provide strategic advantages.
proactiveinvestors.co.uk
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the AIM-listed clinical-stage biopharmaceutical company, has appointed Dr Adrian Kilcoyne to its Scientific Advisory Board, bringing more than 20 years of oncology and immunology drug development experience to the company. Kilcoyne is currently chief medical officer at Cellectis, the French biotechnology company focused on allogeneic CAR-T therapies, which engineer a patient's immune cells to target and destroy cancer.
prnewswire.com
Avis Budget Group Posts $856 Million Net Loss as Revenue Falls Short of Expectations NEW YORK, March 4, 2026 /PRNewswire/ -- Avis Budget Group (NASDAQ: CAR) shareholders suffered significant losses after the company reported a Q4 2025 GAAP net loss of $856 million and revenue that missed analyst consensus estimates by approximately $80 million. If you lost money on your CAR investment, you are encouraged to obtain additional information and submit your details here.
See all news
